China Resources
26 Harbour Road, Wan Chai, Hong Kong Island, Hong Kong
Overview
China Resources (Holdings) Co., Ltd. (“CR” or “China Resources Group”) is a diversified holding company registered in Hong Kong. CR was first established as “Liow & Co.” in Hong Kong in 1938 and was later restructured and renamed as China Resources Company in 1948. In 1952, instead of being affiliated to the General Office of the CPC Central Committee, it came under the Central Trade Department (now known as the Ministry of Commerce). In 1983, it was again restructured into China Resources (Holdings) Co., Ltd. In December 1999, CR was no longer linked to the Ministry of Foreign Trade and Economic Cooperation and came under state management. In 2003, under the direct supervision of SASAC, it became one of the key state-owned enterprises.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Retail
Investment portfolio
- Immunochina
Led · Series C · Jan 2019
艺妙神州 develops CAR‑T gene‑cell therapies targeting malignant tumors and has advanced multiple CAR‑T candidates into clinical trials. The company has obtained three clinical trial approvals from the National Medical Products Administration and received Beijing's first gene‑cell drug production license. Management says these regulatory milestones provide a solid foundation for commercialization of its lead CAR‑T product. In the past year the company has completed multiple financings, and this round brings its year‑to‑date total funding to over RMB 500 million. The newest financing is intended to accelerate the commercial launch and scaling of its first CAR‑T therapy, help overcome overseas technology monopolies, and deliver treatments to hundreds of thousands of lymphoma patients annually. The company cites ongoing innovation in key gene‑cell technologies and milestone achievements as drivers of its development and commercialization plans. Immunochina develops CAR-T cell therapies and a lentiviral manufacturing platform, with a lead product IM19 targeting B‑Cell Acute Lymphoblastic Leukemia (B‑ALL) and Non‑Hodgkin’s Lymphoma and a pipeline for multiple solid and liquid tumors. The company presented positive clinical results from a 110‑patient cohort at ASH showing a 93% complete remission rate and a 1‑year relapse‑free survival of 70.5%, data that supported increased investor interest. Immunochina closed a ¥140 million RMB (~$20.4M USD) Series C to expand GMP‑grade manufacturing and continue clinical trials for IM19. It expects to receive two IND approvals within China by year‑end and is accelerating construction of a commercial‑scale GMP manufacturing facility. The company has partnerships with Sartorius and Thermo Fisher Scientific to support manufacturing scale‑up. Immunochina’s founders are Tsinghua University graduates who lead the company’s end‑to‑end cell therapy R&D efforts.
Team
No current team members are available.